RxDoctor Payments Data

Michael Raines, MD

Family Medicine · Americus, GANPI 1144215872

Payments from drug & device makers

$948in general payments, 2019–2025

Across 53 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$209
  • GSK$185
  • Novartis$92
  • Sumitomo Pharma America, Inc.$89
  • AstraZeneca$79
  • Sunovion Pharmaceuticals Inc.$69
  • plus $223 from 10 others

What the payments were for

  • Food & beverage$948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$948 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$41,659
Medicare patients
321
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban347$154,503
OzempicSemaglutide62$75,083
JanuviaSitagliptin Phosphate181$74,781
XareltoRivaroxaban177$62,207
JardianceEmpagliflozin58$35,578
FarxigaDapagliflozin Propanediol65$33,025
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$30,890
Tresiba Flextouch U-100Insulin Degludec46$30,242
TradjentaLinagliptin64$29,442
NuplazidPimavanserin Tartrate23$28,227
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$24,114
MyrbetriqMirabegron126$23,716
Tresiba Flextouch U-200Insulin Degludec19$22,852
TrulicityDulaglutide25$18,629
AbrysvoRsv Vacc, Pref A And Pref B/Pf53$16,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$17$91,307204 claims
Novo NordiskOzempic$209$75,08362 claims
Johnson & JohnsonXarelto$30$62,207177 claims
AstraZenecaFarxiga, Symbicort$79$42,783101 claims
GSKTrelegy Ellipta, Breo Ellipta$185$39,96459 claims
Astellas Pharma US IncMyrbetriq$12$23,716126 claims
Lilly USA, LLCTrulicity$17$18,62925 claims
NovartisEntresto$92$15,43943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Americus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →